Ocular Therapeutix, Inc. Q3 2025 Earnings Recap

OCUL Q3 2025 November 5, 2025

Get alerts when OCUL reports next quarter

Ocular Therapeutix reported strong progress in its third quarter of 2025 with key milestones reached in its clinical trials for AXPAXLI, positioning the company for a potential market shift in retinal therapies.

Earnings Per Share Beat

$-0.37 vs $-0.39 est.

+5.1% surprise

Revenue Miss

14544000 vs 16142430 est.

-9.9% surprise

Market Reaction

1-Day -0.83%

5-Day -0.64%

30-Day +11.42%

See OCUL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Successfully reached target randomization of 555 subjects in the SOL-R trial for wet AMD, indicating strong investigator engagement and execution.
Launched the HELIOS program aimed at gaining a superiority label for AXPAXLI in both diabetic retinopathy and non-proliferative diabetic retinopathy (NPDR), aiming to capture a broader patient population.
Phase III trial SOL-1 anticipates releasing top-line data in Q1 2026, which could position AXPAXLI as a distinct first-line treatment in a commoditized market currently dominated by anti-VEGF therapies.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit OCUL on AllInvestView.